Results Presented at ICAD 2008 Highlight Significant Improvement in Cognitive Performance and Global Clinical Status in Patients with Alzheimer's Disease

EAST HANOVER, N.J., July 30 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced the launch of Patient Assistance Now -- a new, comprehensive resource that integrates both Novartis and non-Novartis programs that may help uninsured Americans afford their Novartis medicines and find information to take care of their health. Now patients can access an easy-to-use Web site that provides specific information about programs and services available. Patients and caregivers can visit www.PatientAssistanceNow.com or call toll-free 1-800-245-5356 to find programs that may be right for them.

CHICAGO, July 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) presented today positive Phase III data of a once-daily extended-release formulation of Namenda(R) (memantine HCl) at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD). The study evaluated the efficacy, safety and tolerability of an innovative, proprietary, 28 mg once-daily extended-release formulation of Namenda compared to placebo in outpatients with moderate to severe Alzheimer's disease already being treated with a cholinesterase inhibitor (donepezil, galantamine or rivastigmine).

CHICAGO, July 30 /PRNewswire/ -- For many of us, the health of our nails is something we often take for granted. That is until something goes wrong and changes the appearance or texture of the nails. Dermatologists, who are the physician experts in the care of skin, hair and nails, find that brittle nails, nail fungus and problems from nail cosmetics are among the most common sources of nail disorders. Help can be found by seeking proper diagnosis and starting a proven treatment regimen, which can include medications and behavioral changes.

Disruptive Innovations Challenge the Status Quo of U.S. Health Care System, According to Deloitte Center for Health Solutions Research Series

SEATTLE and ATLANTA, July 30 /PRNewswire/ -- A patient with pancreatic cancer recently became the first person in the United States to receive treatment using Elekta VMAT (Volumetric intensity Modulated Arc Therapy) at Seattle's Swedish Cancer Institute. This revolutionary new technology dramatically decreases treatment times -- delivering a higher dose to the tumor target without compromising coverage and patient safety.

Tickets are $150 -- cash or check accepted at the door. For more information on the event or to purchase tickets in advance, please call 973-379-2690 ext. 7131 or visit www.ChristopherReeve.org/hamptons.

NEW YORK, July 30 /PRNewswire/ -- Saks Fifth Avenue and the Entertainment Industry Foundation (EIF) announced today that Academy Award(R) winning actress Gwyneth Paltrow has been named the Entertainment Industry Foundation ambassador for Saks Fifth Avenue's 2008 KEY TO THE CURE campaign. KEY TO THE CURE is a women's cancer initiative founded in partnership with EIF's Women's Cancer Research Fund. The program will also receive ongoing support from Mercedes-Benz USA.

WASHINGTON, July 30 /PRNewswire-USNewswire/ -- The American Lung Association congratulates the U.S. House of Representatives for its historic passage of the Family Smoking Prevention and Tobacco Control Act today. The overwhelming margin of support this legislation received highlights the bipartisan consensus that the time has come for it to become law. The American Lung Association now calls on the U.S. Senate, where the legislation has 57 sponsors, to pass this important public health bill in September.

Clinical Program Leverages Quark's RNAi Technology